Target-In is a world leader in the development of apofusions - a unique,
patented platform based on targeted cell-suicide technology.
A dedicated biotechnology company, Target-In's product offering is based
on genetically engineered protein that mimic natural cell selection and
suicide induction.
|
|
With today's increased demand for new disease-fighting alternatives, and
a heightened awareness of therapeutic, targeted cell-death towards a cure,
the Company predicts the rise of apofusion technology on a global scale.
Target-In will participate in shaping this industry's future.
|